Skip to content

Safety and Effectiveness of the Globe® Pulsed Field System for Treating Patients With Symptomatic Paroxysmal or Persistent Atrial Fibrillation

Persistent Atrial Fibrillation | Paroxysmal Atrial Fibrillation

This study will evaluate the safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal or persistent atrial fibrillation (AF).

null

Participation Requirements

  • Sex:

    ALL
  • Eligible Ages:

    18 to 80

Participation Criteria

Key inclusion criteria:

* A diagnosis of recurrent symptomatic paroxysmal or persistent AF
* Failure or intolerance of at least one antiarrhythmic drug (AAD) Class I or III

Key exclusion criteria:

* Long-standing persistent AF (sustained \>12 months)
* Atrial fibrillation secondary to a reversible cause or of non-cardiac origin
* History of thromboembolic events within the past six months
* Myocardial infarction (MI)/percutaneous coronary intervention (PCI) within the last three months
* Any cardiac surgery within the previous six months
* Prior left atrial ablation or surgical procedure
* Presence of an implanted cardiac device
* Body mass index (BMI) \>40 kg/m\^2
* Left ventricular ejection fraction (LVEF) \<35%
* Anterior-posterior left atrial (LA) diameter \>55mm

Study Location

McGill University Health Centre
McGill University Health Centre
Montréal, Quebec
Canada

Contact Study Team

St.Paul's Hospital
St.Paul's Hospital
Vancouver, British Columbia
Canada

Contact Study Team

Study Sponsored By
Kardium Inc.
Participants Required
More Information
Study ID: NCT05462145